MITech Co

MITech Co EV/Revenue

The EV/Revenue (Enterprise Value to Revenue) of MITech Co (179290.KQ) as of Nov 17, 2026 is 3.23. In the previous year, EV/Revenue (Enterprise Value to Revenue) was 2.76 — a change of 17.14% (higher).

EV/Revenue

3.23

YoY

17.14%

Last updated:

EV/Revenue (Enterprise Value to Revenue) of MITech Co is 2025 3.23 . EV/Revenue (Enterprise Value to Revenue) of MITech Co was 2024 2.76 . It decreases by 17.14% higher compared to the previous year.

The MITech Co EV/Revenue history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/Revenue
Date
EV/Revenue
Jan 1, 2018
6.46 KRW
Jan 1, 2019
6.35 KRW
Jan 1, 2020
5.04 KRW
Jan 1, 2021
3.84 KRW
Jan 1, 2022
3.16 KRW
Jan 1, 2023
3.58 KRW
Jan 1, 2024
2.76 KRW
Jan 1, 2025
3.23 KRW
The MITech Co EV/Revenue history
YEAREV/RevenueYoY
3.23+17.14%
2.76-22.91%
3.58+13.30%
3.16-17.82%
3.84-23.84%
5.04-20.63%
6.35-1.66%
6.46-31.91%
9.49-27.76%
13.14-22.43%
16.94—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MITech Co Stock analysis

What does MITech Co do? M.I.Tech Co., Ltd. generates revenue through the manufacturing and sale of non-vascular stent systems, including biliary, esophagus, pyloric, large intestine, and duodenal stents, as well as stents for sample and study. The company sells these products under the brand names CHOOSTENT and HANAROSTENT, targeting domestic and overseas markets. Additionally, M.I.Tech produces low frequency therapies, crushers, and blood glucose meters, which contribute to its product portfolio. The firm focuses on medical device manufacturing for both domestic and international healthcare providers. The primary customers for M.I.Tech's stents are healthcare institutions and medical professionals requiring stent solutions for various gastrointestinal and biliary conditions. CHOOSTENT and HANAROSTENT are the key branded products driving sales, with the company distributing these devices across Korea and globally. The low frequency therapies, crushers, and blood glucose meters serve complementary medical needs, broadening the company's market reach. M.I.Tech's revenue streams are diversified across stent systems and ancillary medical devices. M.I.Tech Co., Ltd. operates within the medical device sector, specializing in stent systems and related healthcare products. The company's domestic market presence is complemented by international distribution, with its products reaching healthcare facilities in multiple countries. The brand names CHOOSTENT and HANAROSTENT are central to its commercial strategy, emphasizing product differentiation in the stent market. Revenue is derived from direct sales of stents and medical devices to hospitals and clinics worldwide. MITech Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MITech Co stock

EV/Revenue (Enterprise Value to Revenue) of MITech Co is 3.23 in 2025.

EV/Revenue (Enterprise Value to Revenue) of MITech Co changed from 2.76 to 3.23, representing a 17.14% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EV/Revenue (Enterprise Value to Revenue) MITech Co since 2006 – with annual values, charts, and detailed analysis.

The EV/Revenue ratio compares a company's enterprise value to its total revenue. It is particularly useful for valuing high-growth companies that may not yet be profitable.

To evaluate EV/Revenue (Enterprise Value to Revenue)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/Revenue (Enterprise Value to Revenue).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/Revenue (Enterprise Value to Revenue)'s MITech Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — MITech Co

All Key Metrics — MITech Co